A recent real-world study in China sheds light on the effectiveness of ixekizumab, a monoclonal antibody targeting interleukin-17A, in treating plaque psoriasis, particularly in areas like the scalp, nails, joints, palms, and genitals. The study, piloted across 26 hospitals, involving 612 Chinese patients (aged ≥ 18 years) revealed that most patients faced psoriasis in these difficult-to-treat body areas, impacting their quality of life significantly. Almost all of the patients (93.6%) had psoriasis involvement in at least one distinct area of the body.

Despite the challenges posed by psoriasis in these areas, ixekizumab attested to be a game-changer. Patients experienced notable improvements in disease severity and quality of life, with comparable reductions in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores, regardless of psoriasis involvement in special body areas.

These findings not only underscore the consistent effectiveness of ixekizumab but also highlight its potential to bring relief to patients grappling with psoriasis in even the most challenging regions of the body.